Rheumatology

General Infectious Disease

Questions discussed in this category

What is your approach to a patient with undetectable MMR titers checked prior to or during immunosuppression and a history of MMR vaccination in childhood?

Is there a role for booster vaccination and if so, how do you approach the timing when a patient is already on a biologic for immunosuppression?

1 Answer available

Do you recommend chronic oral suppressive antibiotics after initial intensive treatment of 6-8 weeks in patients with culture-negative prosthetic joint or bone infections with retained hardware?

1 Answer available

What are your vaccine recommendations while patients are on biologics?

2 Answers available

Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?

1 Answer available

How do you integrate next-generation sequencing with traditional culture methods to improve the identification of fungal pathogens, especially in cases where routine cultures are negative when evaluating suspected prosthetic joint infections?

2 Answers available

How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?

1 Answer available

What specific criteria or patient conditions would make you hesitant to use fluoroquinolones early in the treatment course for managing MSSA joint infections with oral antibiotics?

For example, baseline QT prolongation, elderly age group, or underlying heart disease?

3 Answers available

Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?

1 Answer available

How often do you see bony erosions in patients with Lyme arthritis?

1 Answer available

Do you find HZV titers useful in diagnosing shingles sine herpete?

1 Answer available

What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?

Would it be safe to resume and if so, when?

2 Answers available

Papers discussed in this category

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015-08-01

Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

The Lancet. Neurology, 2009-08

Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment.

The American journal of medicine, 2024 Mar 16

The Contribution of 18F FDG PET-CT for the Investigation of Fever of Unknown Origin and Inflammation of Unknown Origin.

Related Topics in Rheumatology